TuHURA Biosciences Files 8-K Amendment
Ticker: HURA · Form: 8-K/A · Filed: Aug 12, 2025 · CIK: 1498382
Sentiment: neutral
Topics: amendment, financials, exhibits
Related Tickers: THRX
TL;DR
TuHURA Biosciences filed an 8-K amendment on Aug 12, 2025, updating financials as of June 30, 2025.
AI Summary
TuHURA Biosciences, Inc./NV filed an amendment (Amendment No. 1) to its Form 8-K on August 12, 2025, reporting events as of June 30, 2025. The filing pertains to financial statements and exhibits. The company, formerly known as Kintara Therapeutics, Inc., is incorporated in Nevada and its fiscal year ends on December 31.
Why It Matters
This amendment updates the company's public filings, providing crucial information for investors and stakeholders regarding financial statements and exhibits as of a specific reporting date.
Risk Assessment
Risk Level: low — This filing is an amendment to a previous report and primarily concerns financial statements and exhibits, not a new material event.
Key Numbers
- 001-37823 — SEC File Number (Identifies the company's filing with the SEC)
- 99-0360497 — IRS Employer Identification No. (Company's tax identification number)
Key Players & Entities
- TuHURA Biosciences, Inc./NV (company) — Registrant
- Kintara Therapeutics, Inc. (company) — Former company name
- August 12, 2025 (date) — Filing date of amendment
- June 30, 2025 (date) — Date of earliest event reported
- Nevada (jurisdiction) — State of incorporation
FAQ
What is the purpose of this 8-K/A filing?
This filing is an amendment (Amendment No. 1) to a previously filed Form 8-K, specifically updating financial statements and exhibits as of June 30, 2025.
When was this amendment filed with the SEC?
The amendment was filed on August 12, 2025.
What was TuHURA Biosciences, Inc./NV formerly known as?
The company was formerly known as Kintara Therapeutics, Inc., with previous name changes also noted.
In which state is TuHURA Biosciences, Inc./NV incorporated?
The company is incorporated in Nevada.
What is the business address of TuHURA Biosciences, Inc./NV?
The business address is 10500 University Center Dr., Suite 110, Tampa, Florida 33612.
Filing Stats: 1,015 words · 4 min read · ~3 pages · Grade level 13.1 · Accepted 2025-08-12 16:24:34
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value per share HURA The Nasdaq
Filing Documents
- d67982d8ka.htm (8-K/A) — 32KB
- d67982dex991.htm (EX-99.1) — 288KB
- d67982dex992.htm (EX-99.2) — 373KB
- 0001193125-25-178993.txt ( ) — 909KB
- hura-20250630.xsd (EX-101.SCH) — 3KB
- hura-20250630_lab.xml (EX-101.LAB) — 18KB
- hura-20250630_pre.xml (EX-101.PRE) — 11KB
- d67982d8ka_htm.xml (XML) — 6KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (a) Financial Statements of Businesses Acquired Pursuant to General Instruction B.3 of Form 8-K, the consolidated balance sheets of the acquired company, Kineta, as of December 31, 2024 and 2023, and the related consolidated statements of operations, stockholders' equity (deficit), and cash flows for each of the years ended December 31, 2024 and 2023, and the related notes, are not required in the Original Report, as amended by this Amendment, because "substantially the same" financial statements were previously filed in TuHURA's Registration Statement on Form S-4 (File No. 333-284787), initially filed on February 7, 2025, as amended, and declared effective by the Securities Exchange Commission on May 14, 2025. The unaudited consolidated balance sheets of Kineta as of March 31, 2025 and December 31, 2024, and the related consolidated statements of operations, stockholders' equity (deficit), and cash flows for each of the three months ended March 31, 2025 and 2024, and the related notes, are attached as Exhibit 99.1 to this Amendment and incorporated by reference herein. (b) Pro forma financial information. The following unaudited pro forma financial information of TuHURA is attached as Exhibit 99.2 to this Amendment and incorporated by reference herein: Unaudited Pro Forma Condensed Combined Balance Sheet for TuHURA as of March 31, 2025, on a pro forma basis as if the Mergers and TuHURA's previously announced reverse merger with Kintara Therapeutics, Inc. that closed on October 18, 2024 (the "Kintara Merger", and together with the Mergers, the "Transactions") had been consummated on March 31, 2025. Unaudited Pro Forma Condensed Combined Statements of Operations for TuHURA for the three months ended March 31, 2025, on a pro forma basis as if the Transactions had been consummated on March 31, 2025. Unaudited Pro Forma Condensed Combined Statement of Operations for TuHURA for the year ended December 31, 2024, on a pro
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TUHURA BIOSCIENCES, INC. Date: August 12, 2025 By: /s/ Dan Dearborn Name: Dan Dearborn Title: Chief Financial Officer